Plain-English translation of NCT04953897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing oral decitabine and cedazuridine (), a new combination medication taken by mouth for certain blood cancers like acute myeloid leukemia and myelodysplastic syndrome. The study wants to understand how this medication behaves in the body when someone has severe kidney problems, and compare that to how it works in people with normal kidney function. This information will help doctors know if the dose needs to be adjusted for patients with kidney disease.
Many cancer medications are cleared from the body through the kidneys, so people with kidney problems may need different doses to stay safe. This trial exists to figure out the right dose of this medication for patients whose kidneys aren't working well, so they can receive effective treatment without harmful side effects.
You likely qualify if…
You likely don't qualify if…
You will take the oral medication by mouth as part of one of two groups — either as someone with severely reduced kidney function or as someone with normal kidney function (to serve as a comparison). The study lasts about 8 weeks, during which you'll have blood tests and other monitoring to check how the medication works in your body and whether it's safe. You'll need to attend visits to follow a specific schedule, especially during the first treatment cycle when the researchers are most closely tracking how your body processes the medication.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Armenia